BioCentury | Jan 24, 2011
Regulation

Arguing for Avastin

...smaller one than E2100. Avastin increased PFS by 1.2 months when added on top of anthra-cycline/taxane...
BioCentury | Apr 10, 2006
Company News

Valera, Anthra deal

...VLRX acquired rights to Valstar valrubicin from Anthra for $600,000 plus potential milestones and royalties. The...
...hasn't been sold since 2002, when Anthra ceased operations. Valera Pharmaceuticals Inc. (VLRX), Cranbury, N.J. Anthra Pharmaceuticals Inc....
BioCentury | Jul 24, 2000
Clinical News

Valtaxin valrubicin chemotherapeutic anthracycline derivative regulatory update

...to the compound, which is marketed in the U.S. under the name Valstar , from Anthra Pharmaceuticals Inc....
BioCentury | Jul 18, 2000
Company News

Paladin Labs receives approval for Valtaxin

...to the compound, which is marketed in the U.S. under the name Valstar , from Anthra...
BioCentury | Feb 14, 2000
Company News

Cytogen management update

...Diagnostics/Imaging Hired: Nicholas Borys as VP of medical affairs, formerly VP and medical director at Anthra Pharmaceuticals Inc. WIR...
BioCentury | Feb 7, 2000
Clinical News

Valstar valrubicin regulatory update

...Canada accepted for filing Anthra's new drug submission for Valstar, a chemotherapeutic for intravesical therapy of...
...PLB has exclusive rights in Canada to the product, which is approved in the U.S. Anthra Pharmaceuticals Inc....
BioCentury | Oct 25, 1999
Company News

Anthra, Paladin deal

...PLB received exclusive rights in Canada to Anthra’s Valstar valrubicin, a chemotherapeutic for intravesical therapy of...
...Valstar valrubicin, a chemotherapeutic for intravesical therapy of refractory carcinoma in situ of the bladder. Anthra...
...$1 million equity investment from PLB, and is eligible for $2.25 million in sales-related milestones. Anthra Pharmaceuticals Inc....
BioCentury | Apr 5, 1999
Finance

The barber's chairman

...Ebb & Flow The barber's chairman Meanwhile, Anthra cited market conditions for withdrawing its NASDAQ IPO...
...its NASDAQ IPO. The company is starting to generate royalty revenue, as partner Medeva launched Anthra's...
...Valstar valrubicin in the U.S. in February to treat carcinoma in situ of the bladder. Anthra...
BioCentury | Feb 8, 1999
Company News

Anthra, Medeva Pharmaceuticals Inc. sales and marketing update

...Medeva began U.S. sales of Anthra's Valstar valrubicin to treat carcinoma in situ of the bladder...
...cystectomies. Anthra will receive royalties. Medeva Pharmaceuticals is a subsidiary of Medeva plc (London, U.K.). Anthra Pharmaceuticals Inc....
BioCentury | Oct 5, 1998
Clinical News

Anthra, Medeva Pharmaceuticals Inc. regulatory update

...The FDA granted Orphan Drug status and marketing approval for Valstar , Anthra's anthracycline derivative valrubicin...
...Advisory Committee voted against recommending Valstar to treat all refractory patients (see BioCentury, Sept. 8). Anthra Pharmaceuticals Inc....
Items per page:
1 - 10 of 18
BioCentury | Jan 24, 2011
Regulation

Arguing for Avastin

...smaller one than E2100. Avastin increased PFS by 1.2 months when added on top of anthra-cycline/taxane...
BioCentury | Apr 10, 2006
Company News

Valera, Anthra deal

...VLRX acquired rights to Valstar valrubicin from Anthra for $600,000 plus potential milestones and royalties. The...
...hasn't been sold since 2002, when Anthra ceased operations. Valera Pharmaceuticals Inc. (VLRX), Cranbury, N.J. Anthra Pharmaceuticals Inc....
BioCentury | Jul 24, 2000
Clinical News

Valtaxin valrubicin chemotherapeutic anthracycline derivative regulatory update

...to the compound, which is marketed in the U.S. under the name Valstar , from Anthra Pharmaceuticals Inc....
BioCentury | Jul 18, 2000
Company News

Paladin Labs receives approval for Valtaxin

...to the compound, which is marketed in the U.S. under the name Valstar , from Anthra...
BioCentury | Feb 14, 2000
Company News

Cytogen management update

...Diagnostics/Imaging Hired: Nicholas Borys as VP of medical affairs, formerly VP and medical director at Anthra Pharmaceuticals Inc. WIR...
BioCentury | Feb 7, 2000
Clinical News

Valstar valrubicin regulatory update

...Canada accepted for filing Anthra's new drug submission for Valstar, a chemotherapeutic for intravesical therapy of...
...PLB has exclusive rights in Canada to the product, which is approved in the U.S. Anthra Pharmaceuticals Inc....
BioCentury | Oct 25, 1999
Company News

Anthra, Paladin deal

...PLB received exclusive rights in Canada to Anthra’s Valstar valrubicin, a chemotherapeutic for intravesical therapy of...
...Valstar valrubicin, a chemotherapeutic for intravesical therapy of refractory carcinoma in situ of the bladder. Anthra...
...$1 million equity investment from PLB, and is eligible for $2.25 million in sales-related milestones. Anthra Pharmaceuticals Inc....
BioCentury | Apr 5, 1999
Finance

The barber's chairman

...Ebb & Flow The barber's chairman Meanwhile, Anthra cited market conditions for withdrawing its NASDAQ IPO...
...its NASDAQ IPO. The company is starting to generate royalty revenue, as partner Medeva launched Anthra's...
...Valstar valrubicin in the U.S. in February to treat carcinoma in situ of the bladder. Anthra...
BioCentury | Feb 8, 1999
Company News

Anthra, Medeva Pharmaceuticals Inc. sales and marketing update

...Medeva began U.S. sales of Anthra's Valstar valrubicin to treat carcinoma in situ of the bladder...
...cystectomies. Anthra will receive royalties. Medeva Pharmaceuticals is a subsidiary of Medeva plc (London, U.K.). Anthra Pharmaceuticals Inc....
BioCentury | Oct 5, 1998
Clinical News

Anthra, Medeva Pharmaceuticals Inc. regulatory update

...The FDA granted Orphan Drug status and marketing approval for Valstar , Anthra's anthracycline derivative valrubicin...
...Advisory Committee voted against recommending Valstar to treat all refractory patients (see BioCentury, Sept. 8). Anthra Pharmaceuticals Inc....
Items per page:
1 - 10 of 18